Display options
Cite
Yin M, Kim YO, Choi JI, et al. Antinociceptive role of neurotensin receptor 1 in rats with chemotherapy-induced peripheral neuropathy. Korean J Pain. 2020;33(4):318-325doi: 10.3344/kjp.2020.33.4.318.
Yin, M., Kim, Y. O., Choi, J. I., Jeong, S., Yang, S. H., Bae, H. B., & Yoon, M. H. (2020). Antinociceptive role of neurotensin receptor 1 in rats with chemotherapy-induced peripheral neuropathy. The Korean journal of pain, 33(4), 318-325. https://doi.org/10.3344/kjp.2020.33.4.318
Yin, Mei, et al. "Antinociceptive role of neurotensin receptor 1 in rats with chemotherapy-induced peripheral neuropathy." The Korean journal of pain vol. 33,4 (2020): 318-325. doi: https://doi.org/10.3344/kjp.2020.33.4.318
Yin M, Kim YO, Choi JI, Jeong S, Yang SH, Bae HB, Yoon MH. Antinociceptive role of neurotensin receptor 1 in rats with chemotherapy-induced peripheral neuropathy. Korean J Pain. 2020 Oct 01;33(4):318-325. doi: 10.3344/kjp.2020.33.4.318. PMID: 32989196; PMCID: PMC7532295.
Copy Download .nbib Format: NLM
Share it on

Korean J Pain. 2020 Oct 01;33(4):318-325. doi: 10.3344/kjp.2020.33.4.318.

Antinociceptive role of neurotensin receptor 1 in rats with chemotherapy-induced peripheral neuropathy.

The Korean journal of pain

Mei Yin, Yeo-Ok Kim, Jeong-Il Choi, Seongtae Jeong, Si-Ho Yang, Hong-Beom Bae, Myung-Ha Yoon

Affiliations

  1. Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School, Gwangju, Korea.
  2. The Brain Korea 21 Project, Center for Biomedical Human Resources at Chonnam National University, Gwangju, Korea.

PMID: 32989196 PMCID: PMC7532295 DOI: 10.3344/kjp.2020.33.4.318

Abstract

BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a major side effect of anti-cancer drugs. Neurotensin receptors (NTSRs) are widely distributed within the pain circuits in the central nervous system. The purpose of this study was to determine the role of NTSR1 by examining the effects of an NTSR1 agonist in rats with CIPN and investigate the contribution of spinal serotonin receptors to the antinociceptive effect.

METHODS: Sprague-Dawley rats (weight 150-180 g) were used in this study. CIPN was induced by injecting cisplatin (2 mg/kg) once a day for 4 days. Intrathecal catheters were placed into the subarachnoid space of the CIPN rats. The antiallodynic effects of intrathecally or intraperitoneally administered PD 149163, an NTSR1 agonist, were evaluated. Furthermore, the levels of serotonin in the spinal cord were measured by high-performance liquid chromatography.

RESULTS: Intrathecal or intraperitoneal PD 149163 increased the paw withdrawal threshold in CIPN rats. Intrathecal administration of the NTSR1 antagonist SR 48692 suppressed the antinociceptive effect of PD 149163 given via the intrathecal route, but not the antinociceptive effect of intraperitoneally administered PD 149163. Intrathecal administration of dihydroergocristine, a serotonin receptor antagonist, suppressed the antinociceptive effect of intrathecally administered, but not intraperitoneally administered, PD 149163. Injecting cisplatin diminished the serotonin level in the spinal cord, but intrathecal or intraperitoneal administration of PD 149163 did not affect this reduction.

CONCLUSIONS: NTSR1 played a critical role in modulating CIPN-related pain. Therefore, NTSR1 agonists may be useful therapeutic agents to treat CIPN. In addition, spinal serotonin receptors may be indirectly involved in the effect of NTSR1 agonist.

Keywords: Cisplatin; Dihydroergocristine; Hyperalgesia; Neuralgia; Neurotensin; PD 149163; Peripheral Nervous System Diseases; SR 48692; Serotonin Antagonists; Spinal Cord

References

  1. Pain. 2008 Apr;135(3):280-90 - PubMed
  2. F1000Res. 2016 Jun 22;5: - PubMed
  3. Brain Res. 2001 Nov 16;919(1):1-11 - PubMed
  4. Br J Pharmacol. 2014 Feb;171(3):636-45 - PubMed
  5. Front Neurosci. 2017 Aug 31;11:481 - PubMed
  6. J Biol Chem. 1973 Oct 10;248(19):6854-61 - PubMed
  7. Behav Pharmacol. 2011 Sep;22(5-6):390-404 - PubMed
  8. J Comp Neurol. 1982 Sep 20;210(3):211-24 - PubMed
  9. Pain. 2005 Mar;114(1-2):285-94 - PubMed
  10. Neurochem Int. 2008 Dec;53(6-8):355-61 - PubMed
  11. J Neurochem. 2008 May;105(4):1100-14 - PubMed
  12. Eur J Pain. 2012 Apr;16(4):473-84 - PubMed
  13. J Clin Invest. 2014 Mar;124(3):1199-213 - PubMed
  14. Eur J Neurosci. 1996 Jan;8(1):153-61 - PubMed
  15. Phys Ther. 2010 Nov;90(11):1649-57 - PubMed
  16. Brain Res. 1987 Sep 8;420(1):171-4 - PubMed
  17. Physiol Behav. 1976 Dec;17(6):1031-6 - PubMed
  18. Br J Anaesth. 2017 Oct 1;119(4):737-749 - PubMed
  19. Food Chem Toxicol. 2010 Dec;48(12):3412-7 - PubMed
  20. Brain Res. 1995 Oct 9;695(1):59-63 - PubMed
  21. Semin Oncol Nurs. 2009 May;25(2 Suppl 1):S8-19 - PubMed
  22. Neuropeptides. 1998 Oct;32(5):465-71 - PubMed
  23. Behav Brain Res. 2012 Jun 15;232(1):93-7 - PubMed
  24. Eur J Pharmacol. 2013 Dec 5;721(1-3):201-7 - PubMed
  25. Ann N Y Acad Sci. 1982;400:283-306 - PubMed
  26. Mol Pain. 2009 Jul 06;5:38 - PubMed
  27. Korean J Pain. 2015 Oct;28(4):236-43 - PubMed
  28. Pharmacology. 2020;105(3-4):173-180 - PubMed
  29. Korean J Pain. 2012 Jan;25(1):1-6 - PubMed
  30. FASEB J. 2013 Sep;27(9):3741-52 - PubMed

Publication Types